Navigation Links
MiMedx Announces Record Second Quarter Results
Date:7/31/2013

of 2012. The Company's gross margins for the first half of 2013 were 84% as compared to 76% in the first half of last year.  Adjusted EBITDA for the six months ended June 30, 2013, were $2.3 million, a $1.1 million or 85% improvement as compared to Adjusted EBITDA of $1.2 million for the first six months of 2012. The Net Loss for the six months ended June 30, 2013, was $2.4 million, which included a one-time non-cash charge of $1.3 million in the first quarter of 2013 for debt discount related to the conversion of the Company's senior secured promissory notes.

Management Commentary on Second Quarter Results
Parker H. "Pete" Petit, Chairman and CEO, stated, "We are pleased with our revenue performance as we exceeded the $13.5 million upper range of our goal and achieved greater than a 175% increase over our 2012 second quarter revenue. This was our 7th straight quarter of meeting or exceeding our revenue forecast. We continued to produce strong gross profit margins, equaling our fourth quarter of 2012 and first quarter of 2013 record gross margins of 84%.  Management continues to focus on EBITDA and balancing EBITDA growth and the investments in our sales organization required to drive revenue. We are pleased with our diligence in this area and our success in recording our sixth consecutive quarter of positive Adjusted EBIDTA."

The Company's second quarter revenue growth was driven primarily by its EpiFix® wound care allografts as well as its micronized tissue for both wound care and sports medicine applications. "Most notable in our second quarter results is the positive growth in commercial accounts driven by the five Medicare Administrative Contractors (MACs) that have already approved coverage of EpiFix®. During the quarter, we received coverage from another of the MACs. That coverage by Wisconsin Physician Services (WPS) now brings the total MACs covering our EpiFix® wound care tissue grafts to six of the nin
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
2. MiMedx To Exceed High End Of Second Quarter Guidance
3. MiMedx to Ring NASDAQ Stock Market Opening Bell
4. MiMedx to Present at Jefferies 2013 Global Healthcare Conference
5. MiMedx Secures a $3.0 Million Revolving Line of Credit with Bank of America
6. MiMedx Announces Record First Quarter 2013 Results
7. MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
8. MiMedx Group, Inc. Announces Release Date for 2013 First Quarter Results
9. MiMedx Responds To Inquiries Regarding Trading Activity; Reiterates First Quarter And Full Year Goals
10. MiMedx to Present at the Canaccord Genuity Musculoskeletal Conference
11. MiMedx Is Issued Four Additional U.S. Patents For Placental Tissue Grafts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... (PRWEB) December 19, 2014 Bioject ... developer and manufacturer of needle-free injection technology, today ... with Immunomic Therapeutics, Inc. (“ITI”) for ITI to ... with its LAMP™ vaccine platform. , In ... exclusive Worldwide license to the Biojector®-2000 that triggers ...
(Date:12/19/2014)... 19, 2014 BioPlus Specialty Pharmacy ... announces the promotion of Nick Maroulis, Pharm.D. to the ... Services. , In this position, Dr. Maroulis will ... managing the directors of our multi-site pharmacies as the ... 1997 and during that time he has served in ...
(Date:12/19/2014)... , Dec. 19, 2014  Roche (SIX: RO, ROG; ... Technologies, Inc. (Bina), a privately held company based ... USA. Bina provides a big data platform for ... (NGS) data. Bina,s proprietary on-market Genomic Management Solution, ... researchers to perform fast and scalable analyses to ...
(Date:12/19/2014)... Dec. 19, 2014 Decision Resources Group finds ... at a 12 percent compound annual growth rate through ... aging population and the increasing adoption of dental implants. ... will also spur demand for dental biomaterials because ... and periodontal treatments. Other key findings from ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3
... Jan. 3 Escalon Medical Corp.,(Nasdaq Capital Market: ... 510(k) clearance from the U.S. Food and Drug,Administration ... The MASTER-VU(TM) System consists of a B-scan probe ... (via a USB cable,connection) using Sonomed,s proprietary software, ...
... Jan. 3 Cinpathogen, through its,partnership in the ... clinical diagnostic technology consulting,services to Shanghai area hospitals. ... the,Shanghai Health Study, the Center has diagnosed and ... in collaboration with area,hospitals and colleagues at Fudan ...
... KENILWORTH, N.J., Jan. 2 Schering-Plough,Corporation (NYSE: ... and Drug,Administration (FDA) has assigned priority review status ... Sugammadex is specifically designed to reverse the ... States as ZEMURON(R) (rocuronium,bromide) and vecuronium bromide. Muscle ...
Cached Biology Technology:Escalon(R) Announces FDA 510(k) Clearance for Sonomed MASTER-VU(TM) B-Scan System 2Escalon(R) Announces FDA 510(k) Clearance for Sonomed MASTER-VU(TM) B-Scan System 3Cinpathogen Provides Clinical Diagnostic Consulting Services to Shanghai Area Hospitals 2Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 2Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 3Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 4
(Date:12/19/2014)... , Dec. 18, 2014 Research and ... the addition of the "iPhone 5S Fingerprint ... Report" report to their offering. ... the acquisition of AuthenTec in July 2012, Apple ... 5S. It is currently the only device of ...
(Date:12/19/2014)... , Dec. 18, 2014  23andMe, Inc., the ... a study that pinpoints fine-scale differences in genetic ancestry ... . Since immigrants first arrived more ... States has served as a meeting place ... American history and the ongoing mixing of peoples with ...
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) ... Galaxy S5 - Home Button Synaptics Fingerprint Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the iPhone 5S, Samsung introduces for the first ... The Galaxy S5 home button presents an ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... New York University biologists have uncovered how the innate ... neurons. The findings, published as the cover study in ... neurons fight the virus at multiple stages--by preventing the ... virus' release, which could infect other cells in the ...
... today in the journal Genome,Research that they have ... a 554-kilobase-pair genomic,segment near the centromere of the ... genes that could be implicated in,sex-associated height differences ... one of the few holes remaining in the,"finished" ...
... in comparison to the 3.2 gigabases of its human ... 14 proteins, which play different roles in promoting viral ... host’s cellular machinery—including RNA polymerases, which carry out transcription—to ... chromosomal DNA. Once the virus is integrated (now called ...
Cached Biology News:NYU Study Reveals How Brain's Immune System Fights Viral Encephalitis 2Found: Missing sequence of the human Y chromosome 2Found: Missing sequence of the human Y chromosome 3Novel Enzyme Shows Potential As An Anti-HIV Target 2Novel Enzyme Shows Potential As An Anti-HIV Target 3